Here are the 10-K annual reports from MIRA Pharmaceuticals, Inc. (MIRA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MIRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIRA filings page.
MIRA Pharmaceuticals, Inc. reports its annual results as a clinical-stage biotech with no revenue and a substantial accumulated deficit of $39.6 million as of December 31, 2025. The company warns of substantial doubt about its ability to continue as a going concern beyond the third quarter of 2025 without new financing.
MIRA is advancing three oral drug candidates: Ketamir-2 for neuropathic pain, MIRA-55 for inflammatory and CNS-related pain, and SKNY-1 for obesity and nicotine dependence. Ketamir-2 has completed Phase 1 dosing with no serious adverse events reported to date, and a Phase 2a trial in chemotherapy-induced peripheral neuropathy is planned for 2026, subject to regulatory review and resources.
The DEA has concluded that Ketamir-2, MIRA-55, and SKNY-1 are not currently controlled substances, which may ease development. However, operations rely heavily on external licensing (notably from MIRALOGX), at-the-market equity sales, and a very small team of two part-time employees and consultants, underscoring execution and financing risk.